Onalespib(AT13387,ATI13387X) chemical structure
Chemical structureResearch use only
CAT. NO. DC8167Featured

Onalespib(AT13387,ATI13387X)

Pack Sizes & Prices

TotalUS$450
We match the best price and quality on market.
Product overview

Description & Application

AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. in vitro: AT13387 is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. AT13387 is a selective potent heat shock protein 90 (Hsp90) inhibitor with IC50 of 18 nM in A375 cells. The Kd for AT13387 binding is 0.7 nM. in vivo: AT13387 could be tolerated at doses of up to 70 mg/kg twice weekly or 90 mg/kg once weekly. Body weight loss in mice does not exceed 20% before recovering in all cases except one, and loss is highest following the second dose. Tumor growth inhibition is similar in NCI-H1975 for both dosing regimens. The maintenance of antitumor effects with such a prolonged off-treatment period is consistent with the extended pharmacodynamic action of AT13387 observed for mutant EGFR and other biomarkers in vitro and in vivo and the extended retention of AT13387 in tumors. For the detailed information of Onalespib(AT13387,ATI13387X), the solubility of Onalespib(AT13387,ATI13387X) in water, the solubility of Onalespib(AT13387,ATI13387X) in DMSO, the solubility of Onalespib(AT13387,ATI13387X) in PBS buffer, the animal experiment (test) of Onalespib(AT13387,ATI13387X), the cell expriment (test) of Onalespib(AT13387,ATI13387X), the in vivo, in vitro and clinical trial test of Onalespib(AT13387,ATI13387X), the EC50, IC50,and affinity,of Onalespib(AT13387,ATI13387X), For the detailed information of Onalespib(AT13387,ATI13387X), the solubility of Onalespib(AT13387,ATI13387X) in water, the solubility of Onalespib(AT13387,ATI13387X) in DMSO, the solubility of Onalespib(AT13387,ATI13387X) in PBS buffer, the animal experiment (test) of Onalespib(AT13387,ATI13387X), the cell expriment (test) of Onalespib(AT13387,ATI13387X), the in vivo, in vitro and clinical trial test of Onalespib(AT13387,ATI13387X), the EC50, IC50,and affinity,of Onalespib(AT13387,ATI13387X), Please contact DC Chemicals.

ParameterValue
Chemical NameOnalespib free base
CAS No.912999-49-6
SynonymsAT13387; AT-13387; AT 13387; Onalespib; Onalespib lactate.
FormulaC24H31N3O3
M.Wt409.52
SMILESO=C(C1=CC(C(C)C)=C(O)C=C1O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. in vitro: AT13387 is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. AT13387 is a selective potent heat shock protein 90 (Hsp90) inhibitor with IC50 of 18 nM in A375 cells. The Kd for AT13387 binding is 0.7 nM. in vivo: AT13387 could be tolerated at doses of up to 70 mg/kg twice weekly or 90 mg/kg once weekly. Body weight loss in mice does not exceed 20% before recovering in all cases except one, and loss is highest following the second dose. Tumor growth inhibition is similar in NCI-H1975 for both dosing regimens. The maintenance of antitumor effects with such a prolonged off-treatment period is consistent with the extended pharmacodynamic action of AT13387 observed for mutant EGFR and other biomarkers in vitro and in vivo and the extended retention of AT13387 in tumors. For the detailed information of Onalespib(AT13387,ATI13387X), the solubility of Onalespib(AT13387,ATI13387X) in water, the solubility of Onalespib(AT13387,ATI13387X) in DMSO, the solubility of Onalespib(AT13387,ATI13387X) in PBS buffer, the animal experiment (test) of Onalespib(AT13387,ATI13387X), the cell expriment (test) of Onalespib(AT13387,ATI13387X), the in vivo, in vitro and clinical trial test of Onalespib(AT13387,ATI13387X), the EC50, IC50,and affinity,of Onalespib(AT13387,ATI13387X), For the detailed information of Onalespib(AT13387,ATI13387X), the solubility of Onalespib(AT13387,ATI13387X) in water, the solubility of Onalespib(AT13387,ATI13387X) in DMSO, the solubility of Onalespib(AT13387,ATI13387X) in PBS buffer, the animal experiment (test) of Onalespib(AT13387,ATI13387X), the cell expriment (test) of Onalespib(AT13387,ATI13387X), the in vivo, in vitro and clinical trial test of Onalespib(AT13387,ATI13387X), the EC50, IC50,and affinity,of Onalespib(AT13387,ATI13387X), Please contact DC Chemicals.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Solution calculator

Related research products

SNX-5422(PF04929113) chemical structureDC9948

SNX-5422(PF04929113)

SNX-5422 (PF-04929113), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37 nM.

View activity & prices
VER155008 chemical structureDC8299

VER155008

VER-155008 is an inhibitor of Hsp70, with IC50s of 0.5 μM, 2.6 μM, and 2.6 μM for Hsp70, Hsc70 and Grp7, respectively, and with a Kd of 0.3 μM for Hsp70.

View activity & prices
ML-346 chemical structureDC9994

ML-346

ML346 is an activator of Hsp70 expression and HSF-1 activity, with an EC50 of 4.6 μM for Hsp70. ML346 restores protein folding in conformational disease models, without significant cytotoxicity or lack of specificity.…

View activity & prices

Cart

Request quotation